Kincell Bio remote jobs and company guide

We are Kincell Bio, a technology-forward contract development and manufacturing organization (CDMO) with a clear and dedicated mission: to help cell therapy innovators successfully advance their products from the earliest stages of clinical supply to late-stage development and commercial launch. We spun out of Inceptor Bio in 2023, born from the understanding that emerging biotech companies need a partner that thinks and operates with the same urgency and innovative mindset that they do. Our team is comprised of seasoned product developers and scientific experts with a long history in large pharma, academic research, and the fast-paced startup environment. This unique blend of experience allows us to provide not just manufacturing services, but also deep scientific and strategic guidance. We pride ourselves on being a true extension of our clients' teams, offering a personalized and expert-driven approach to process development and manufacturing.

Our facilities, located in Gainesville, Florida, and the Research Triangle Park in North Carolina, are equipped to handle a wide range of immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK, and CAR-M programs. We understand the immense challenges and complexities involved in bringing a cell therapy to market. That's why we focus on streamlining CMC (Chemistry, Manufacturing, and Controls) development, applying our expertise in analytical and process development, and ensuring the highest standards of GMP (Good Manufacturing Practice) manufacturing, testing, and release. We are committed to a collaborative and responsive service model, ensuring that we are not just a service provider, but a dedicated partner in our clients' journey to deliver life-saving therapies to patients with unmet medical needs. We are passionate about accelerating the progress of cell therapy innovation by making manufacturing more accessible and streamlined, ultimately bringing these groundbreaking treatments to the patients who need them most.